NCT03127449View on ClinicalTrials.gov

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

NATerminatedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

May 12, 2021

Study Completion Date

January 8, 2024

Conditions
Advanced NSCLC
Interventions
DRUG

Alflutinib

patients take Alflutinib orally once per day at different dose

Trial Locations (1)

Unknown

cancer hospital Chinese academy of medical sciences, Beijing

Sponsors
All Listed Sponsors
lead

Allist Pharmaceuticals, Inc.

INDUSTRY

NCT03127449 - AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations | Biotech Hunter | Biotech Hunter